"uuid:ID","id","name","rationale","label","description","instanceType"
"00c06058-661d-4e73-b250-1d182e0e955c","StudyDesign_1","Study Design 1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","","The main design for the study","StudyDesign"
